Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2020 Aug 5.

Published in final edited form as: Clin Cancer Res. 2019 May 29;25(16):4973–4984. doi: 10.1158/1078-0432.CCR-19-0197

Figure 4. — Examples of individual patient graphs showing matching rise in CA 19–9 and KRAS ctDNA in a patient with recurrence (A), similar stability in CA 19–9 and KRAS ctDNA in a patient without recurrence (B), rise in KRAS ctDNA with low and stable CA 19–9 in a patient with recurrence (C), rise in KRAS ctDNA in nonexpressor of CA 19–9 with recurrence (D), KRAS ctDNA response to treatment (E and F), and a patient in whom KRAS ctDNA might have helped clinical decision-making (G). Red line signifies mutant KRAS droplets per 10k total droplets over time. Dark blue line signifies CA 19–9 levels in U/mL over time. Green plane signifies chemotherapy treatment. CAP, capecitabine; FFX, FOLFIRINOX; GEM, gemcitabine; GTX/Cis, gemcitabine, docetaxel, capecitabine and cisplatin; NAB-P; nab-paclitaxel. Yellow plane signifies radiotherapy. SBRT, stereotactic body radiation therapy. Light blue arrow signifies lead time of KRAS ctDNA detection relative to clinical recurrence. • signifies clinical disease recurrence; * signifies patient death; (−) signifies a negative KRAS ctDNA result; (±) signifies a borderline KRAS ctDNA result; (+) signifies a positive KRAS ctDNA result. Sample at time point 0 represents the preoperative sample.

Inline graphic — Examples of individual patient graphs showing matching rise in CA 19–9 and KRAS ctDNA in a patient with recurrence (A), similar stability in CA 19–9 and KRAS ctDNA in a patient without recurrence (B), rise in KRAS ctDNA with low and stable CA 19–9 in a patient with recurrence (C), rise in KRAS ctDNA in nonexpressor of CA 19–9 with recurrence (D), KRAS ctDNA response to treatment (E and F), and a patient in whom KRAS ctDNA might have helped clinical decision-making (G). Red line signifies mutant KRAS droplets per 10k total droplets over time. Dark blue line signifies CA 19–9 levels in U/mL over time. Green plane signifies chemotherapy treatment. CAP, capecitabine; FFX, FOLFIRINOX; GEM, gemcitabine; GTX/Cis, gemcitabine, docetaxel, capecitabine and cisplatin; NAB-P; nab-paclitaxel. Yellow plane signifies radiotherapy. SBRT, stereotactic body radiation therapy. Light blue arrow signifies lead time of KRAS ctDNA detection relative to clinical recurrence. • signifies clinical disease recurrence; * signifies patient death; (−) signifies a negative KRAS ctDNA result; (±) signifies a borderline KRAS ctDNA result; (+) signifies a positive KRAS ctDNA result. Sample at time point 0 represents the preoperative sample.